Alexandra N. Trelle, Christina B. Young, Hillary Vossler, Javier Ramos Benitez, Karly A. Cody, Justin H. Mendiola, Michelle S. Swarovski, Yann Le Guen, Igor Feinstein, Robert R. Butler, Divya Channappa, America Romero, Jennifer Park, Marian Shahid-Besanti, Nicole K. Corso, Kelly Chau, Amanda N. Smith, Irina Skylar-Scott, Maya V. Yutsis, Carolyn A. Fredericks, Lu Tian, Kyan Younes, Geoffrey A. Kerchner, Gayle K. Deutsch, Guido A. Davidzon, Sharon J. Sha, Victor W. Henderson, Frank M. Longo, Michael D. Greicius, Tony Wyss-Coray, Katrin I. Andreasson, Kathleen L. Poston, Anthony D. Wagner, Elizabeth C. Mormino, Edward N. Wilson
{"title":"Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum","authors":"Alexandra N. Trelle, Christina B. Young, Hillary Vossler, Javier Ramos Benitez, Karly A. Cody, Justin H. Mendiola, Michelle S. Swarovski, Yann Le Guen, Igor Feinstein, Robert R. Butler, Divya Channappa, America Romero, Jennifer Park, Marian Shahid-Besanti, Nicole K. Corso, Kelly Chau, Amanda N. Smith, Irina Skylar-Scott, Maya V. Yutsis, Carolyn A. Fredericks, Lu Tian, Kyan Younes, Geoffrey A. Kerchner, Gayle K. Deutsch, Guido A. Davidzon, Sharon J. Sha, Victor W. Henderson, Frank M. Longo, Michael D. Greicius, Tony Wyss-Coray, Katrin I. Andreasson, Kathleen L. Poston, Anthony D. Wagner, Elizabeth C. Mormino, Edward N. Wilson","doi":"10.1002/alz.14442","DOIUrl":null,"url":null,"abstract":"The availability of amyloid beta (Aβ) targeting therapies for Alzheimer's disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"79 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.14442","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The availability of amyloid beta (Aβ) targeting therapies for Alzheimer's disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
